ShRNA-mediated BAALC knockdown affects proliferation and apoptosis in human acute myeloid leukemia cells

Hematology

Volumn 17, Issue 1, 2012, Pages 35-40

  Xu, Bing ^a   Chen, Guoshu ^a   Shi, Pengcheng ^a   Guo, Xutao ^a   Xiao, Pingnan ^a   Wang, Weiguang ^b   Zhou, Shuyun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

AML; Apoptosis; BAALC; Proliferation; ShRNA

Indexed keywords

MESSENGER RNA; PLASMID VECTOR; SHORT HAIRPIN RNA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BRAIN AND ACUTE LEUKEMIA CYTOPLASMIC GENE; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; WESTERN BLOTTING;

APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84863096254     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13221316477499     Document Type: Article

References (22)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368:1894-1907.
2. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol. 2004;50:197-222.
3. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol. 2004;5:443-450.
4. Avivi I, Rowe JM. Prognostic factors in acute myeloid leukemia. Curr Opin Hematol. 2005;12:62-67.
5. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011 Feb 10;29(5):475-486.
6. Marchesi F, Annibali O, Cerchiara E, Tirindelli MC, Avvisati G. Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: A concise review. Crit Rev Oncol Hematol. 2011;80(3):331-346.
7. Mrózek K, Heerema NA, In acute leukemia. Blood Rev. 2004;18:115-136.
8. Zheng J, Wang X, Hu Y, Yang J, Liu J, He Y, et al. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China. Cytometry B Clin Cytom. 2008;74:25-29.
9. Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005;23:482-493.
10. Dunna NR, Rajappa S, Digumarti R, Vure S, Kagita S, Damineni S, et al. Fms Like Tyrosine Kinase (FLT3) and Nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML). Asian Pac J Cancer Prev. 2010;11:1811-1816.
11. Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A, et al. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol. 2011;29:682-689.
12. Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117:2469-2475.
13. Baldus CD, Tanner SM, Kusewitt DF, Chapelle A. BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol. 2003;31(11):1051-1056.
14. Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A. 2001,98(24):13901-13906.
15. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008;111(11):5371-5379.
16. Eid MA, Attia M, Abdou S, El-Shazly SF, Elahwal L, Farrag W, et al. BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis. Int J Lab Hematol. 2010;32(2):197-205.
17. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(25):5660-5669.
18. Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, et al. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate- risk acute myeloid leukemia (AML). Ann Hematol. 2010;89(5):453-458.
19. Kurreck J. RNA interference: From basic research to therapeutic applications. Angew Chem Int Ed Engl. 2009;48(8): 1378-1398.
20. Angaji SA, Hedayati SS, Poor RH, Madani S, Poor SS, Panahi S. Application of RNA interference in treating human diseases. J Genet. 2010;89:527-537.
21. Heesch S, Schlee C, Neumann M, Stroux A, Kühnl A, Schwartz S, et al. BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia. 2010;24:1429-1436.
22. Zaidi SZ, Owaidah T, Al Sharif F, Ahmed SY, Chaudhri N, Aljurf M. The challenge of risk stratification in acute myeloid leukemia with normal karyotype. Hematol Oncol Stem Cell Ther. 2008;1:141-158.